X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TORRENT PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES TORRENT PHARMA DIVIS LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x 31.3 29.0 107.9% View Chart
P/BV x 5.4 5.5 98.3% View Chart
Dividend Yield % 0.9 1.0 92.5%  

Financials

 DIVIS LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
TORRENT PHARMA
Mar-17
DIVIS LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2221,768 69.1%   
Low Rs7841,186 66.1%   
Sales per share (Unadj.) Rs153.1346.1 44.2%  
Earnings per share (Unadj.) Rs39.955.2 72.4%  
Cash flow per share (Unadj.) Rs44.673.3 60.8%  
Dividends per share (Unadj.) Rs10.0014.00 71.4%  
Dividend yield (eoy) %1.00.9 105.2%  
Book value per share (Unadj.) Rs201.8257.1 78.5%  
Shares outstanding (eoy) m265.47169.22 156.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.3 153.6%   
Avg P/E ratio x25.126.8 93.8%  
P/CF ratio (eoy) x22.520.1 111.7%  
Price / Book Value ratio x5.05.7 86.5%  
Dividend payout %25.025.4 98.7%   
Avg Mkt Cap Rs m266,266249,887 106.6%   
No. of employees `0009.711.8 82.6%   
Total wages/salary Rs m4,6879,934 47.2%   
Avg. sales/employee Rs Th4,175.04,971.5 84.0%   
Avg. wages/employee Rs Th481.5843.2 57.1%   
Avg. net profit/employee Rs Th1,089.3792.4 137.5%   
INCOME DATA
Net Sales Rs m40,64358,569 69.4%  
Other income Rs m7492,233 33.5%   
Total revenues Rs m41,39260,802 68.1%   
Gross profit Rs m14,46013,773 105.0%  
Depreciation Rs m1,2333,069 40.2%   
Interest Rs m232,056 1.1%   
Profit before tax Rs m13,95310,881 128.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3491,545 216.8%   
Profit after tax Rs m10,6049,336 113.6%  
Gross profit margin %35.623.5 151.3%  
Effective tax rate %24.014.2 169.0%   
Net profit margin %26.115.9 163.7%  
BALANCE SHEET DATA
Current assets Rs m40,10553,841 74.5%   
Current liabilities Rs m6,59531,612 20.9%   
Net working cap to sales %82.538.0 217.2%  
Current ratio x6.11.7 357.1%  
Inventory Days Days11997 122.0%  
Debtors Days Days8184 96.3%  
Net fixed assets Rs m19,99542,079 47.5%   
Share capital Rs m531846 62.7%   
"Free" reserves Rs m53,04342,655 124.4%   
Net worth Rs m53,57443,501 123.2%   
Long term debt Rs m022,408 0.0%   
Total assets Rs m61,585101,250 60.8%  
Interest coverage x618.46.3 9,826.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.70.6 114.1%   
Return on assets %17.311.3 153.4%  
Return on equity %19.821.5 92.2%  
Return on capital %26.119.6 132.9%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38420,066 176.3%   
Fx outflow Rs m10,3995,304 196.0%   
Net fx Rs m24,98514,762 169.2%   
CASH FLOW
From Operations Rs m11,49310,127 113.5%  
From Investments Rs m-11,372-7,869 144.5%  
From Financial Activity Rs m-93-1,918 4.9%  
Net Cashflow Rs m28212 13.4%  

Share Holding

Indian Promoters % 52.0 71.5 72.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 7.0 168.1%  
FIIs % 19.0 12.6 150.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.8 195.5%  
Shareholders   31,796 26,511 119.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS